Solara Active Pharma Sciences Limited (NSE:SOLARA)
518.85
-15.45 (-2.89%)
Jan 23, 2026, 3:29 PM IST
Solara Active Pharma Sciences Employees
Solara Active Pharma Sciences had 1,775 employees as of March 31, 2025. The number of employees decreased by 381 or -17.67% compared to the previous year.
Employees
1,775
Change (1Y)
-381
Growth (1Y)
-17.67%
Revenue / Employee
6.79M INR
Profits / Employee
36.11K INR
Market Cap
24.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 1,775 | -381 | -17.67% |
| Mar 31, 2024 | 2,156 | -205 | -8.68% |
| Mar 31, 2023 | 2,361 | 107 | 4.75% |
| Mar 31, 2022 | 2,254 | -321 | -12.47% |
| Mar 31, 2021 | 2,575 | 179 | 7.47% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Akums Drugs and Pharmaceuticals | 7,536 |
| Indoco Remedies | 6,000 |
| Aarti Pharmalabs | 2,162 |
| Innova Captab | 1,600 |
| Sigachi Industries | 1,507 |
| Jagsonpal Pharmaceuticals | 1,399 |
| Windlas Biotech | 1,346 |
| RPG Life Sciences | 1,331 |
Solara Active Pharma Sciences News
- 2 months ago - Solara Active Pharma’s Mangalore facility clears US FDA inspection with VAI classification - Business Upturn
- 2 months ago - Solara Active Pharma Sciences Ltd (BOM:541540) Q2 2026 Earnings Call Highlights: Navigating ... - GuruFocus
- 2 months ago - Q2 2026 Solara Active Pharma Sciences Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - Solara Active Pharma shares slump nearly 9% today after reporting Q2 net loss - Business Upturn
- 9 months ago - Solara Active Pharma shares rise 4% after Ambernath facility clears USFDA inspection with zero observations - Business Upturn
- 11 months ago - Solara Active Pharma shares down 5% as Managing Director Poorvank Purohit resigns - Business Upturn
- 1 year ago - Solara Active Pharma Sciences announces demerger of CRAMS and Polymers business - Business Upturn
- 1 year ago - Solara Active Pharma Sciences Q3 FY25 Results: Revenue up 41.6% YoY to Rs 300.31 crore - Business Upturn